Skip to main content

Table 3 Changes in cardiopulmonary function of the participants after the 6-week intervention from baseline

From: Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study

  control Group Lower Dosage Medium Dosage High Dosage Time P value T × D P value
∆O2-pulse max (L/min/bpm) 0.73 (− 0.23, 1.68) 1.25 (0.23,2.27) 0.82 (0.07, 1.70) 1.17 (0.32, 2.02) < 0.01 0.56
∆RER max 0.09 (0.00, 0.18) −0.02 (− 0.07, 0.07) 0.05 (− 0.16, 0.11) 0.03 (− 0.08, 0.14) 0.04 0.36
(L/min) 0.18 (0.02, 0.36) 0.23 (0.09,0.37) 0.26 (1.74, 0.35) 0.32 (0.20, 0.43) < 0.01 0.48
∆ Peak power (Mets) 0.72 (−0.04, 1.49) 1.05 (0.45,1.65) 1.18 (0.78, 1.58) 1.45 (0.86, 2.06) < 0.01 0.31
∆Peak workload (W) 10.9 (−2.47, 24.24) 11.25 (−0.43, 22.93) 13.58 (5.44, 21.7) 13.93 (8.92, 18.95) < 0.01 0.58
∆HR@VT1 (bpm) 5.8& (0.3, , 11.4) 5.2& (1.1, 9.2) 12.8 (7.8, 17.8) 16.0 (10.4, 21.5) < 0.01 < 0.01
∆O2-pulse @VT1 (L/min/bpm) 0.55 (−0.37, 1.46) 1.17 (0.71,1.62) 0.92 (0.17, 2.20) 2.00 (1.23, 2.77) < 0.01 0.10
@VT1 (L/min) 0.17#& (0.09, 0.24) 0.24& (0.18,0.30) 0.33 (0.25, 0.41) 0.47 (0.34, 0.60) < 0.01 < 0.01
∆Power @AVT1 (Mets) 0.69#& (0.35, 1.03) 1.06& (0.80,1.31) 1.41& (1.02, 1.79) 2.13 (1.56, 2.69) < 0.01 < 0.01
∆% @VT1 (%) 2.1& (−0.85, 1.49) 3.5& (0.05,7.00) 6.5 (3.62, 9.43) 10.3 (7.61,13.05) < 0.01 < 0.01
∆HR@VT2 (bpm) 5.6 (1.9, 9.4) 6.7 (3.2, 10.2) 10.8 (4.5, 17.2) 12.4 (4.4, 20.5) < 0.01 0.23
∆O2-pulse @VT2 (L/min/bpm) 0.55 (−0.37, 1.47) 1.58 (0.95,2.22) 0.50 (0.04, 1.91) 1.67 (0.72, 2.62) < 0.01 0.16
@VT2 (L/min) 0.20 (0.03, 1.49) 0.39 (0.26,0.52) 0.33 (0.22, 0.44) 0.44 (0.29, 0.58) < 0.01 0.06
∆ Power @VT2 (Mets) 0.78 (0.07, 1.49) 1.78 (1.20,2.35) 1.56 (1.00, 2.11) 2.04 (1.34, 2.73) < 0.01 0.03
∆% @VT2 (%) 1.55 (−1.75, 4.84) 6.67 (3.20,10.10) 4.25 (1.28, 7.22) 6.58 (3.57, 9.59) < 0.01 0.06
∆O2/∆WR slope (ml/min/w) 0.11 (−0.58, 0.79) 0.44 (−0.16,1.04) 0.58 (0.01, 1.16) 0.69 (0.06, 1.45) < 0.01 0.56
  1. Note: The difference of parameter between pre and post intervention among four groups were performed using one-way ANOVA. #VS medium dosage, P <  0.05, &VS large dosage, P <  0.05
  2. ANOVA for repeated measurement for interaction of time (T) and dose (D). bpm, beat per minute